Compare Stocks → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:CYTTNASDAQ:NVCTNASDAQ:RLMDNASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTTCyteir Therapeutics$3.01-0.3%$3.01$1.65▼$3.19$108.35M0.09N/A551,300 shsNVCTNuvectis Pharma$6.77-0.9%$6.68$5.85▼$18.46$124.27M0.4982,154 shs51,266 shsRLMDRelmada Therapeutics$3.01$3.60$2.36▼$7.22$90.81M0.39102,237 shs21,629 shsRZLTRezolute$3.95-23.4%$3.45$0.72▼$6.10$158.51M1.311.24 million shs4.32 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTTCyteir Therapeutics0.00%0.00%0.00%+300,999,900.00%+300,999,900.00%NVCTNuvectis Pharma-0.88%+6.78%+1.80%-38.45%-62.82%RLMDRelmada Therapeutics0.00%+2.03%-13.51%-44.46%+17.12%RZLTRezolute-23.45%-30.94%+49.06%+121.91%+99.49%Discover How to Turn $10,000 into $1 Million (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTTCyteir TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVCTNuvectis Pharma1.8416 of 5 stars3.50.00.00.02.75.00.0RLMDRelmada Therapeutics2.7952 of 5 stars2.51.00.04.42.51.70.6RZLTRezolute3.6314 of 5 stars4.53.00.00.02.75.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTTCyteir TherapeuticsN/AN/AN/AN/ANVCTNuvectis Pharma3.00Buy$21.00210.19% UpsideRLMDRelmada Therapeutics1.00Sell$13.50348.50% UpsideRZLTRezolute3.00Buy$9.67144.73% UpsideCurrent Analyst RatingsLatest CYTT, NVCT, RZLT, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2024RLMDRelmada TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Sell$3.00 ➝ $2.006/4/2024RZLTRezoluteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/22/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/16/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/8/2024NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTTCyteir TherapeuticsN/AN/AN/AN/A$4.13 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$2.84 per shareN/ARZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTTCyteir Therapeutics-$46.06M-$0.94N/A∞N/AN/A-24.88%-23.83%N/ANVCTNuvectis Pharma-$22.26M-$1.41N/AN/AN/AN/A-141.57%-103.98%8/14/2024 (Estimated)RLMDRelmada Therapeutics-$98.79M-$3.13N/AN/AN/AN/A-102.09%-91.30%8/13/2024 (Estimated)RZLTRezolute-$51.79M-$1.14N/AN/AN/AN/A-60.90%-54.58%9/12/2024 (Estimated)Latest CYTT, NVCT, RZLT, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q3 2024RZLTRezolute-$0.34-$0.34N/A-$0.34N/AN/A5/8/2024Q1 2024RLMDRelmada Therapeutics-$0.90-$0.72+$0.18-$0.72N/AN/A5/7/2024Q1 2024NVCTNuvectis Pharma-$0.40-$0.25+$0.15-$0.25N/AN/A3/19/2024Q4 2023RLMDRelmada Therapeutics-$0.88-$0.84+$0.04-$0.84N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTTCyteir TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTTCyteir TherapeuticsN/A21.8921.89NVCTNuvectis PharmaN/A3.463.46RLMDRelmada TherapeuticsN/A6.826.82RZLTRezoluteN/A11.8211.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTTCyteir Therapeutics63.24%NVCTNuvectis Pharma96.77%RLMDRelmada Therapeutics45.24%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipCYTTCyteir Therapeutics14.40%NVCTNuvectis Pharma38.85%RLMDRelmada Therapeutics18.00%RZLTRezolute20.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTTCyteir Therapeutics4636.00 million30.81 millionN/ANVCTNuvectis Pharma1318.36 million11.23 millionNot OptionableRLMDRelmada Therapeutics2030.17 million24.74 millionOptionableRZLTRezolute5740.13 million31.79 millionOptionableCYTT, NVCT, RZLT, and RLMD HeadlinesRecent News About These CompaniesJune 15 at 10:40 AM | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Purchases 4,300 Shares of StockJune 15 at 9:35 AM | insidertrades.comBrian Kenneth Roberts Purchases 4,300 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 14 at 1:49 PM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Purchases 4,300 SharesJune 13 at 11:30 PM | globenewswire.comRezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded WarrantsJune 13 at 4:01 PM | globenewswire.comRezolute Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 13 at 9:26 AM | americanbankingnews.comShort Interest in Rezolute, Inc. (NASDAQ:RZLT) Rises By 162.0%June 13 at 9:24 AM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Short Interest UpdateJune 7, 2024 | americanbankingnews.comAnalysts Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $9.67June 5, 2024 | americanbankingnews.comRezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Craig HallumJune 4, 2024 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from AnalystsJune 4, 2024 | marketbeat.comRezolute (NASDAQ:RZLT) Research Coverage Started at Craig HallumMay 30, 2024 | globenewswire.comRezolute to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2024 | insidertrades.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Buys 7,500 SharesMay 28, 2024 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Insider Purchases $20,175.00 in StockMay 22, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 22, 2024 | msn.comWhy Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?May 22, 2024 | markets.businessinsider.comRezolute’s RZ402 Shows Promising Efficacy and Safety in DME Treatment, Reinforcing Buy RatingMay 22, 2024 | marketbeat.comRezolute (NASDAQ:RZLT) Rating Reiterated by HC WainwrightMay 21, 2024 | globenewswire.comRezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 17, 2024 | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyteir TherapeuticsNASDAQ:CYTTCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Nuvectis PharmaNASDAQ:NVCTNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Relmada TherapeuticsNASDAQ:RLMDRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.